【Asset for Licensing】Orally available selective KAT6A/B small-molecule inhibitor

Asset: Orally available selective KAT6A/B small-molecule inhibitor
Development Stage: Clinical stage
Indication: Breast Cancer
Key Asset Highlights:
（1）Demonstrates potent pharmacological inhibitory activity and high selectivity against KAT6A/B histone acetyltransferases, a novel epigenetic driver closely implicated in oncogenic transcription and malignant proliferation of breast cancer.
（2）Effectively modulates epigenetic signaling pathways, downregulates the expression of core oncogenic genes, and induces robust tumor cell cycle arrest and apoptosis in breast cancer preclinical models.
（3）Exhibits prominent differentiated advantages against drug-resistant and recurrent breast cancer subtypes, providing a novel epigenetic therapeutic strategy for patients with unmet clinical needs.
（4）Shows strong synergistic anti-tumor effects in combination with conventional targeted therapy and endocrine therapy, supporting versatile oral combination regimens to improve clinical therapeutic outcomes.
（5）Features favorable oral pharmacokinetic behaviors and a wide safety window, enabling convenient oral administration and sustainable long-term clinical intervention for malignant breast tumors.
（6）Backed by a solid and comprehensive intellectual property portfolio, ensuring stable and exclusive global development and commercialization rights for breast cancer epigenetic treatment.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.